Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study | Zendy

Minh Patrick Lê | Zendy; MarieLaure Chaix | Zendy; Sylvie Chevret | Zendy; Julie Bertrand | Zendy; F. Raffi | Zendy; Sébastien Gallien | Zendy; El Mountacer Billah El Abbassi | Zendy; Christine Katlama | Zendy; Pierre Delobel | Zendy; Yazdan Yazdanpanah | Zendy; Juliette Saillard | Zendy; JeanMichel Molina | Zendy; Gilles Peytavin | Zendy; Diane Ponscarme | Zendy; C. Lascoux | Zendy; Pierre Marie Girard | Zendy; A. Rami | Zendy; Anne Simon | Zendy; Roland Tubiana | Zendy; Claudine Duvivier | Zendy; Vincent Jeantils | Zendy; D Loreillard | Zendy; Isabelle PoizotMartin | Zendy; Louis Bernard | Zendy; Guillaume Gras | Zendy; Clotilde Allavena | Zendy; Eric Billaud | Zendy; Sabelline Bouchez | Zendy; Nancy Hall | Zendy; Véronique Reliquet | Zendy; P. de Truchis | Zendy; Isabelle Charreau | Zendy; L Bocquet | Zendy; Vincent Le Moing | Zendy; G Point | Zendy; Ebrahim Abassi | Zendy; Pierre Tattevin | Zendy; S. Couffin-Cadiergues | Zendy; Isabelle Madelaine | Zendy; Alpha Diallo | Zendy; Séverine Gibowski | Zendy

Open Access

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

Author(s) -

Minh Patrick Lê,

MarieLaure Chaix,

Sylvie Chevret,

Julie Bertrand,

F. Raffi,

Sébastien Gallien,

El Mountacer Billah El Abbassi,

Christine Katlama,

Pierre Delobel,

Yazdan Yazdanpanah,

Juliette Saillard,

JeanMichel Molina,

Gilles Peytavin,

Diane Ponscarme,

C. Lascoux,

Pierre Marie Girard,

A. Rami,

Anne Simon,

Roland Tubiana,

Claudine Duvivier,

Vincent Jeantils,

D Loreillard,

Isabelle PoizotMartin,

Louis Bernard,

Guillaume Gras,

Clotilde Allavena,

Eric Billaud,

Sabelline Bouchez,

Nancy Hall,

Véronique Reliquet,

P. de Truchis,

Isabelle Charreau,

L Bocquet,

Vincent Le Moing,

G Point,

Ebrahim Abassi,

Pierre Tattevin,

S. Couffin-Cadiergues,

Isabelle Madelaine,

Alpha Diallo,

Séverine Gibowski

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky193

Subject(s) - darunavir , ritonavir , pharmacokinetics , regimen , pharmacology , medicine , bioequivalence , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy

In the ANRS 165 DARULIGHT study (NCT02384967) carried out in HIV-infected patients, the use of a darunavir/ritonavir-containing regimen with a switch to a reduced dose of darunavir maintained virological efficacy (≤50 copies/mL) for 48 weeks with a good safety profile.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research